Therefore, we conducted this research to assess the potential therapeutic benefit of canagliflozin on CDD/DEN/TAA-induced HCC in rats and explore the role of AMPK/YAP/TAZ pathways that are known to mediate the advancement of liver cancer. The gene discussed is YAP1; the disease is hepatocellular carcinoma.